Drug Pipeline

Calderasib Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
11
Active Studies
11
Recruiting
5
Phase 3
1
Top Sponsors
14
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-09 NCT06345729
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS…
Trial sites expanded: 222 -> 225 locations
2026-06-09 NCT06997497
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People…
Trial sites expanded: 192 -> 196 locations
2026-06-09 NCT07190248
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With…
Trial sites expanded: 170 -> 175 locations
2026-06-04 NCT07554339
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell…
Recruitment opened
2026-06-04 NCT07554339
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell…
Trial sites expanded: 0 -> 5 locations
2026-06-04 NCT07431827
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC…
Trial sites expanded: 24 -> 36 locations
2026-05-30 NCT07190248
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With…
Trial sites expanded: 160 -> 170 locations
2026-05-30 NCT06997497
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People…
Trial sites expanded: 187 -> 192 locations
2026-05-27 NCT07190248
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With…
Trial sites expanded: 156 -> 160 locations
2026-05-27 NCT06997497
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People…
Trial sites expanded: 180 -> 187 locations
2026-05-27 NCT07286149
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer…
Trial sites expanded: 12 -> 18 locations
2026-05-19 NCT07190248
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With…
Trial sites expanded: 153 -> 156 locations
2026-05-15 NCT06997497
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People…
Trial sites expanded: 161 -> 180 locations
2026-05-15 NCT07286149
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer…
Trial sites expanded: 4 -> 12 locations
Active Studies by Phase
Phase 3
5
Phase 2
2
Phase 1/2
1
Phase 1
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07431827 MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC… Non-small Cell Lung Cancer Recruiting
NCT07554339 A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell… Non-small Cell Lung Cancer Recruiting
NCT06345729 A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS… Non-small Cell Lung Cancer Recruiting
NCT06997497 A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People… Colon Adenocarcinoma Recruiting
NCT07190248 A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With… Non-small Cell Lung Cancer Recruiting
Phase 2
NCT07252739 KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With… Malignant Neoplasm Recruiting
NCT07209111 A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors… Neoplasm Malignant Recruiting
Phase 1/2
NCT07286149 A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer… Lung Neoplasm Malignant Recruiting
Phase 1
NCT07219550 A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy… Healthy Recruiting
NCT05853367 Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) Metastatic Solid Tumors Recruiting
NCT05067283 A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) Advanced Solid Tumors Recruiting
Sponsors Running Calderasib Trials
Disease Areas
Get alerts when Calderasib trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free